Press Releases in 2007

Check out the latest press releases from Novus. For direct media requests, contact us at novus@novusbio.com.
View Press Releases From: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Novus Biologicals Has Conjugation Kits!

Release Date: 
Wednesday, October 24, 2007 - 06:00

Novus Biologicals Has Conjugation Kits! Novus Biologicals is now the U.S. distributor for Innova Biosciences. We now carry conjugation kits that work with only 30 seconds of hands on time, and do not require large antibody volumes! They're called Lightning Link Conjugation Kits, and they are the easiest to use conjugation system in the world, no kidding! You can conjugate to HRP, biotin, fluorescein, b-phycoerythrin, r-phycoerythrin, alkaline phosphatase, allophycocyanin, and glucose oxidase.

Antibody grants from Novus

Release Date: 
Thursday, October 18, 2007 - 06:00

The Antibody Grant program is designed to allow researchers to have their new ideas for an antibody to be produced at no cost to the researcher. After production (generally 4-5 months from idea to affinity purified rabbit sera), the researcher will receive a 0.2 mg test sample. Once initial testing is done and supplied to Novus the researcher will receive the other 1.8 mg supply totaling 2 mg. A grant will be selected on the 15th of every month from grants submitted on our before the end of the previous month.

Novus launches Abnova MaxPab Antibodies

Release Date: 
Monday, October 8, 2007 - 06:00

MaxPab® is a new collection of polyclonal antibodies generated from annotated, sequence verified full-length proteins. Each MaxPab® antibody is validated with a full-length human protein expressed from a mammalian transfected lysate, demonstrating high reactivity, sensitivity and specificity. In addition, MaxPab® antibody has the ability to recognize both linear and conformational protein epitopes for maximum antibody performance! Novus Biologicals' is Abnova's North American distributor of these exciting new research tools.

Novus launches NEW product guarantee!

Release Date: 
Wednesday, September 19, 2007 - 06:00

GUARANTEE PLUS Our goal is to empower you, the researcher, to perform the best research possible. We strive to make and sell antibodies that are novel, useful and accurate. We want you to be completely satisfied with your purchase. Guarantee: We stand behind our products 100%! If you cannot get a product to work in an application and species stated in our datasheet, we will help you get it to work, or you can receive a replacement or a refund. Our guarantee covers 100% of the products we carry, even those from Abnova. It’s that simple!

Novus Biologicals, Inc Ranks No. 3362 on the 2007 Inc. 5,000 with Three-Year Sales Growth of 90.6%

Release Date: 
Thursday, August 23, 2007 - 06:00

MEDIA CONTACT: Bryan Tinsley, 303-730-1950, bryan@novusbio.com FIRST-EVER LIST OF THE 5,000 FASTEST-GROWING BUSINESSES REPORTS TOTAL REVENUE OF $194.5 BILLION Novus Biologicals, Inc Ranks No. 3362 on the 2007 Inc. 5,000 With Three-Year Sales Growth of 90.6% NEW YORK, August 23, 2007 – Inc. today ranked Novus Biologicals on its first-ever Inc. 5,000 list of the fastest-growing private companies in the country. The Inc. 5,000, an extension of Inc. magazine’s annual Inc. 500 list, catches many businesses that are too big to grow at the pace required to make the Inc.

Hydroxylated HIF-1 alpha antibody from Novus Biologicals

Release Date: 
Tuesday, August 7, 2007 - 06:00

Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. HIF-1 is a nuclear protein involved in mammalian oxygen homeostasis. This occurs as a posttranslational modification by prolyl hydroxylation.

Preconjugated Hypoxia antibodies

Release Date: 
Sunday, July 22, 2007 - 06:00

Novus Biologicals now offers preconjugated antibodies for Hypoxia research. The conjugates include Biotin, HRP, and HyLite Fluor 488. These are preconjugated to our HIF-1 alpha antibodies (NB100-105, NB100-123, NB100-131), HIF-2 alpha antibodies (NB100-122, NB100-132), and carbonic anhydrase IX antibody (NB100-417). Biotin conjugated antibodies will be labelled as follows: NB100-105B for the biotin conjugated version of NB100-105. HRP version of NB100-105 is NB100-105H and the HyLite Fluor 488 is NB100-105L.

Preconjugated Autophagy Antibodies

Release Date: 
Sunday, July 22, 2007 - 06:00

Novus Biologicals now offers preconjugated antibodies for Autophagy research. The conjugates include Biotin, HRP, and HyLite Fluor 488. These are preconjugated to our LC3 antibodies (NB100-2220, NB100-2331) and LC3B antibody (NB600-1384). Biotin conjugated antibodies will be labelled as follows: NB100-2220B for the biotin conjugated version of NB100-2220. HRP version of NB100-2220 is NB100-2220H and the HyLite Fluor 488 is NB100-2220L.

Novus Biologicals and AnaSpec Sign Licensing Agreement for HiLyte Dyes

Release Date: 
Saturday, July 21, 2007 - 06:00

July 21, 2008 - San Jose, CA AnaSpec and Novus Biologicals today announced a licensing agreement that will allow Novus Biologicals to label Novus antibodies with AnaSpec HiLytePlus and HiLyte Fluor dyes. HiLytePlus and HiLyte Fluor are AnaSpec's proprietary series of high performance fluorescent dyes optimized for long wavelength biomarker labeling. "Novus Biologicals has established a strong reputation in the scientific community as a provider of high-quality antibodies," noted Dr. Anita Hong, AnaSpec's president.